Teijin and BioVaram Form Strategic Alliance to Expand Usage of Regenerative Medicine Products and Implantable Medical Devices in Japan and India
Hyderabad-based biotechnology company BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT) and Japan’s company Teijin Limited announced today that they have signed a business alliance agreement to explore opportunities for expanding usage of Teijin Group’s implantable medical devices and regenerative medicine products in India, as well as introducing BioVaram’s product portfolio into the Japanese market.
The two companies share a vision to address unmet medical needs in Japan—one of the world’s most advanced healthcare markets—and India, where healthcare innovation is accelerating. This alliance aims to leverage each company’s strengths to deliver cutting-edge solutions across both nations.
Under the agreement, Teijin and BioVaram will explore:
– Regulatory approval and commercialization of SYNFOLIUMⓇ, a cardiovascular repair patch by Teijin Medical Technologies Co., Ltd., in India.
– Opportunities for expanding use of Japan Tissue Engineering Co., Ltd.’s regenerative medicine products in India. Japan Tissue Engineering (J-TEC) is part of the Teijin Group.
– Development and commercialization in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.
Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited., said “The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin’s global expansion in the fields of regenerative medicine and implantable medical devices. By combining the exceptional technological capabilities and extensive expertise of both companies across the distinct markets of Japan and India, we are confident in our ability to deliver innovative therapies that address unmet medical needs in both countries.”
